118 related articles for article (PubMed ID: 29251676)
1. Frontline therapy of ovarian cancer: trials and tribulations.
Volpe J; Filipi JG; Cooper OR; Penson RT
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):1-6. PubMed ID: 29251676
[TBL] [Abstract][Full Text] [Related]
2. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
3. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
4. Cancer research in the United States: A critical review of current status and proposal for alternative models.
Kantarjian HM; Prat F; Steensma DP; Kurzrock R; Stewart DJ; Sekeres MA; Leveque J
Cancer; 2018 Jul; 124(14):2881-2889. PubMed ID: 29757456
[No Abstract] [Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
7. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
8. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances.
Liu J; Matulonis UA
Clin Cancer Res; 2014 Oct; 20(20):5150-6. PubMed ID: 25320365
[TBL] [Abstract][Full Text] [Related]
9. [History of cancer therapy].
Yamabe T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():22-7. PubMed ID: 15535200
[No Abstract] [Full Text] [Related]
10. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer: a brief historical overview of intraperitoneal trials.
Kwa M; Muggia F
Ann Surg Oncol; 2014 May; 21(5):1429-34. PubMed ID: 24081795
[TBL] [Abstract][Full Text] [Related]
12. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
13. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
14. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
15. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer treatments on the horizon.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
[No Abstract] [Full Text] [Related]
17. Targeted agents and combinations in ovarian cancer: where are we now?
McLachlan J; Lima JP; Dumas L; Banerjee S
Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
[TBL] [Abstract][Full Text] [Related]
18. Impact of doxorubicin on survival in advanced ovarian cancer.
A'Hern RP; Gore ME
J Clin Oncol; 1995 Mar; 13(3):726-32. PubMed ID: 7884432
[TBL] [Abstract][Full Text] [Related]
19. Robert Ozols receives important Cancer Research Award.
Anticancer Drugs; 2002 Jul; 13(6):671-2. PubMed ID: 12187918
[No Abstract] [Full Text] [Related]
20. The impact of molecular targets in cancer drug development: major hurdles and future strategies.
Hebar A; Valent P; Selzer E
Expert Rev Clin Pharmacol; 2013 Jan; 6(1):23-34. PubMed ID: 23272790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
